Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
1.020
+0.010 (0.99%)
At close: Oct 30, 2026, 4:00 PM EDT
1.058
+0.038 (3.70%)
After-hours: Oct 30, 2026, 6:34 PM EDT
Lisata Therapeutics Employees
Lisata Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 5 or 19.23% compared to the previous year. That makes Lisata Therapeutics the 38,313th largest employer in the world and 5,485th in the United States.
Employees
21
Change (1Y)
-5
Growth (1Y)
-19.23%
Revenue / Employee
$4,762
Profits / Employee
-$696,238
Market Cap
9.19M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -5 | -19.23% |
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Dec 31, 2023 | 25 | -2 | -7.41% |
| Dec 31, 2022 | 27 | 0 | - |
| Dec 31, 2021 | 27 | 3 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| IN8bio | 18 |
| Moleculin Biotech | 17 |
| Lantern Pharma | 16 |
| Theriva Biologics | 16 |
| Actuate Therapeutics | 12 |
| Ensysce Biosciences | 10 |
| Immuron | 8 |
LSTA News
- 12 days ago - Lisata Therapeutics Proxy statement: Proxy filing - Filings
- 17 days ago - Lisata Therapeutics Appoints Jeff Farrow to Board of Directors - GlobeNewsWire
- 23 days ago - Lisata Therapeutics granted U.S. patent for certepetide in pancreatic cancer - TheFly
- 23 days ago - Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors - GlobeNewsWire
- 24 days ago - Lisata Therapeutics Proxy statement: Proxy filing - Filings
- 26 days ago - Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly - GlobeNewsWire
- 5 weeks ago - Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement - GlobeNewsWire